AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Effective In Wilson Disease
Executive Summary
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
You may also be interested in...
Orphalan Flies Solo In US After Wilson’s Disease Drug Win
Naseem Amin, the privately owned group’s CEO, tells Scrip that, just as in Europe, Orphalan has the resources to commercialize Cuvrior in the US: “We understand the market and we don't need external partners."
Orphalan Cuvrior Earned Earlier Use With Head-To-Head Trial Against Frontline Wilson’s Disease Drug
French orphan specialist developed new assay for primary endpoint to show non-inferiority of its room temperature-stable salt of trientine, earning a broader FDA approval than generically available second-line trientine products.
AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.